EU GMP Chapter 5: production requirements

In short: EU GMP Chapter 5 describes production controls for human medicines, from material handling through processing and packaging. This overview is for pharmaceutical manufacturing, QA and QC teams preparing procedures or reviewing production controls. It summarizes the chapter in original wording; it is not an inspection checklist or a substitute for the full applicable requirements.

Scope of this overview

The European Commission lists EudraLex Volume 4, Part I, Chapter 5: Production as in operation since 1 March 2015. The chapter covers production operations, starting materials, processing, packaging, finished products and certain rejected, recovered or returned materials. Related requirements in other chapters and annexes also apply, depending on the product and activity.

“Minimum requirements” can be misleading if read as a universal checklist. The applicable controls depend on the product, manufacturing authorization, marketing authorization and process. This page gives a structured orientation to the chapter’s subjects; teams should use the official text and applicable product documents when deciding what their site needs.

General production controls

Production should take place under approved instructions and appropriate supervision. Materials and products need suitable controls during receipt, storage, dispensing, processing, packaging and distribution. Procedures and records should support identification, traceability and review of the work performed.

On receipt, compare incoming consignments with the order and approved supplier information. Check the condition and identification of containers, and route damage or other concerns through the applicable quality process. Starting materials and finished products should have a clear status while awaiting the required decision for use or distribution. Intermediate or bulk material received from another source should be handled using controls appropriate to its stage and status.

Store materials and products under conditions established for them, with arrangements that support identification and separation of batches or status categories. During operations, identify materials, equipment and relevant work areas so personnel can determine what product or material is present and what stage of work is underway. Use current procedures for material movement and transfer between equipment or areas.

Production records should document relevant operations and support review of results and discrepancies. Compare actual yields or reconciliations with the approved criteria where the process requires it. Investigate unexplained discrepancies through the site’s quality system. Any departure from an instruction should be handled through the approved deviation process, with assessment and authorization as applicable.

Prevent mix-ups and contamination

Plan work so that product identity and status remain clear and contamination risks are controlled. The control strategy may involve separation of people, materials, equipment or operations; line clearance; cleaning; closed transfers; suitable airflow or containment; or other measures. The specific combination depends on the product and the quality risk assessment.

Assess cross-contamination risks using relevant product and process knowledge. Factors can include the properties of the active substance, how the process generates or transfers residues, the design and shared use of facilities and equipment, cleaning performance, personnel and material flows, and the ability of analytical methods to measure relevant residues. Use the assessment to justify whether controls such as dedicated equipment or areas are needed and how the selected controls will be checked.

Technical and organisational measures are possible risk controls, not a universal set that every site must apply in the same way. Examples include contained processing or transfer, local dust extraction, suitable equipment design, dedicated product-contact parts, campaign scheduling followed by effective cleaning, controlled gowning, and documented handling of spills or contaminated waste. The quality system should define the measures selected for the actual risks and review whether they remain effective.

Starting-material management

Supplier selection and ongoing approval should be part of the pharmaceutical quality system. The level of oversight should reflect material and supply-chain risks. Maintain evidence supporting supplier approval and ensure that quality expectations are clear between the manufacturer and supplier.

Receiving controls should establish that the delivered material and its documentation correspond to approved purchasing and supplier information. Keep batches identifiable through sampling, testing, release and dispensing. Dispensing should follow written instructions and use suitable, identified containers. The responsibilities for testing and acceptance should be defined in the applicable procedures and authorization documents.

For active substances, preserve suitable supply-chain information and assess relevant risks from the source through receipt and use. Where testing is outsourced or supplier data are used, define the justification and oversight in the quality system and applicable regulatory commitments. Do not use a general web checklist to decide that testing can be reduced or transferred.

Processing operations

Before starting an operation, confirm that the work area and equipment are suitable for the next activity and that materials, documents or residues from a previous operation that could create a risk have been addressed. Follow the approved manufacturing formula and processing instructions, including relevant process parameters, sampling, in-process checks and environmental controls.

Keep intermediate and bulk products under conditions appropriate to their quality and stage. Validate critical processes as required by the applicable control strategy and maintain the records that support the validation conclusion. Record significant deviations or yield differences and assess them before proceeding or making a batch decision.

Any recovery or reprocessing activity needs prior assessment under an approved procedure. Consider the potential effect on quality and shelf life, define the conditions and testing needed, and document authorization and outcome. Returned product that has left the manufacturer’s control requires a documented assessment of its history, condition and storage before any decision about reuse or reissue. When quality cannot be established, do not assume the material is suitable for reuse.

Packaging operations

Packaging controls should reduce the risk of mix-ups, substitution and contamination. Before a line or area is used, clear it of items from previous operations that are not required for the current job and document the checks specified by the approved procedure. Verify that product and packaging materials match the approved packaging instructions.

Control printed packaging components so that they remain identifiable and protected from unintended access or use. Follow approved issue, return and destruction procedures. Verify variable information such as batch coding against the instructions, and record the checks required by the process. Reconcile bulk product and printed components where required; investigate and resolve unexplained differences before the batch proceeds through disposition.

In-process packaging checks should be selected for the operation and defined in approved instructions. Examples include checking package completeness, product and component identity, printed information and operation of relevant line controls. Do not copy a checklist from another product without confirming that it fits the approved packaging process.

Finished-product status and other materials

Keep finished product under the required status and storage conditions until the authorized release decision is complete. Clearly identify rejected material and control it to prevent unintended use. Any return, recovery or reprocessing should be assessed and recorded under approved procedures, with the appropriate quality review.

Applying the chapter at a site

Use the official Chapter 5 text alongside the chapters and annexes relevant to your manufacturing activities. For example, premises and equipment, documentation, validation, quality control, sterile manufacture and batch release are addressed elsewhere in EudraLex Volume 4. The correct scope depends on the product and process.

Site-specific items such as role assignments, status-label colours, review frequency, local checklists or acceptance limits are examples in-house criteria unless a specific applicable requirement sets them. Record the basis for such criteria in the approved quality system and do not present a locally selected value as a universal EU rule.

For a site outside the EU, first identify the laws and authorizations that apply to that site and product. EU GMP is relevant where the EU framework applies, but this summary alone cannot establish whether a particular facility, product or export arrangement meets all applicable obligations.

Related reading

• Minimum requirements for EU GMP premises and equipment
• Prevention of cross-contamination in the pharmaceutical industry
• Process validation

Frequently asked questions

Is this a complete EU GMP inspection checklist?

No. It is an overview of production topics in Chapter 5. An inspection or compliance assessment can involve other EudraLex chapters, annexes, authorizations, site procedures and product-specific controls.

Does Chapter 5 prescribe the same cross-contamination controls for every product?

The controls should address the assessed risk. Technical and organisational options need to be selected and justified for the product, process, equipment and facility concerned.

Can a manufacturing site use the same production procedure for every product?

Procedures should fit the approved process and product requirements. Shared procedures may be used where they are appropriate and controlled, but product-specific instructions and controls must remain clear.

Where should an Indian site check its own legal requirements?

Consult the current Indian laws and official notifications that apply to the site and product. This EU-focused overview does not establish Indian regulatory obligations.

References

• European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part I, Chapter 5: Production, revised 2015, in operation since 1 March 2015. Official EudraLex index and Chapter 5 document.